奈达铂联合紫杉醇治疗晚期食管癌的临床观察

目的 观察奈达铂联合紫杉醇治疗晚期食管癌的效果和安全性.方法 68例晚期食管鳞癌初治患者完全随机分为2组：观察组（34例）采用奈达铂联合紫杉醇方案化疗;对照组（34例）采用顺铂联合紫杉醇方案化疗,3周1个疗程,结果 观察组和对照组患者的有效率分别为52.9%（18/34）和47.1%（16/34）,差异无统计学意义（P〉0.05）.2组患者大部分治疗相关不良反应是轻中度,观察组的不良反应主要是中性粒细胞及血小板减少,对照组的不良反应主要是恶心、呕吐.与对照组比较,白细胞减少Ⅰ度,血小板减少Ⅱ度,恶心、呕吐0度、Ⅱ、Ⅲ度差异均有统计学意义（P〈0.05）.结论奈达铂联合紫杉醇方案与顺铂联合紫杉醇方案治疗晚期食管癌疗效相近,但不良反应方面奈达铂联合紫杉醇方案更具优势.

Clinical observations of nedaplatin combined with paclitaxel treating advanced esophageal carcinoma

Objective To evaluate the efficiency and safety of nedaplatin combined with paclitaxel treating advanced esophageal carcinoma. Methods Sixty-eight initial-treated patients with advanced esophageal squamous carcinoma were randomly divided into two groups： observation group （thirty-four patients with advanced esophageal carcinoma） received chemotherapy with nedaplatin and paclitaxel; control group （thirty-four patients with advanced esophageal carcinoma） received no more than six courses of chemotherapy with cisplatin and paclitaxel, and each course was three weeks. Results The effective rate of observation group and control group was respectively 52.9% （18/34） and 47.1% （16/34）. The difference between the two groups was not statistically significant （P〉0.05）. Most of patients in the groups had mild-to-moderate adverse reactions; the adverse reactions of control group were nausea and vomiting. Compared with control group, leukopenia of observation group was grade I and thrombocytopenia was grade II. The differences of grade 0, grade II and III of nausea and vomiting had statistical significant （P〈0.05）. Conclusion Nedaplatin combined with paclitaxel treating advanced esophageal carcinoma has a similar effectiveness with less adverse effects than cisplatin combined with paclitaxel.